Literature DB >> 9199452

The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin.

C Fréhel1, C Offredo, C de Chastellier.   

Abstract

Murine bone marrow-derived macrophages (Mphis) infected with virulent strains of Mycobacterium avium (TMC 724 and a human clinical isolate) or with an avirulent opaque variant that spontaneously dissociates from the virulent human clinical isolate were subjected to a prolonged and continuous treatment with clarithromycin added at the MIC. The efficiency of this antibiotic in terms of inhibition of bacterial growth and bacterial degradation was evaluated during a 21-day treatment period. Growth was assessed by determination of CFU of intracellular bacteria and by a quantitative ultrastructural analysis which allowed us also to determine the extent of bacterial degradation. A similar treatment was applied to the same strains growing in liquid medium. Our data show that in liquid medium, clarithromycin caused a 90% decrease in CFU within 7 days of treatment. When applied to Mphis infected with virulent M. avium, clarithromycin immediately arrested bacterial growth but was unable to fully kill and degrade intracellularly growing virulent bacteria. After 21 days of treatment, 25% of intracellular bacteria were still morphologically intact. These bacteria resumed growth upon removal of the antibiotic, with a normal replication rate. These bacteria had not become more resistant to the drug, since the MIC was unchanged as compared to the one determined for the initial stock used to infect Mphis. Our data therefore suggest that the intraphagosomal environment protects bacteria from degradation. We propose that the inability of the drug to completely destroy bacteria is the result of a limited accessibility of the drug due to prevention of fusions between the immature phagosomes in which virulent bacteria reside and lysosomes in which clarithromycin accumulates. In accord with our proposal, we show that the avirulent opaque variant, which does not prevent phagosome-lysosome fusions (unpublished data), is finally destroyed by clarithromycin even within the phagosomal environment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9199452      PMCID: PMC175394          DOI: 10.1128/iai.65.7.2792-2802.1997

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  38 in total

1.  Extracellular and intracellular activities of clarithromycin used alone and in association with ethambutol and rifampin against Mycobacterium avium complex.

Authors:  N Rastogi; V Labrousse
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

Review 2.  Structure, function and biogenesis of the cell envelope of mycobacteria in relation to bacterial physiology, pathogenesis and drug resistance; some thoughts and possibilities arising from recent structural information.

Authors:  M R McNeil; P J Brennan
Journal:  Res Microbiol       Date:  1991-05       Impact factor: 3.992

3.  MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages.

Authors:  N Mor; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1993-01       Impact factor: 5.191

4.  Inhibition of intracellular growth of Mycobacterium avium by one pulsed exposure of infected macrophages to clarithromycin.

Authors:  N Mor; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

5.  Mycobacterium avium strains resistant to clarithromycin and azithromycin.

Authors:  L Heifets; N Mor; J Vanderkolk
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

6.  A simple method for counting adherent cells: application to cultured human monocytes, macrophages and multinucleated giant cells.

Authors:  A Nakagawara; C F Nathan
Journal:  J Immunol Methods       Date:  1983-01-28       Impact factor: 2.303

7.  Lack of acidification in Mycobacterium phagosomes produced by exclusion of the vesicular proton-ATPase.

Authors:  S Sturgill-Koszycki; P H Schlesinger; P Chakraborty; P L Haddix; H L Collins; A K Fok; R D Allen; S L Gluck; J Heuser; D G Russell
Journal:  Science       Date:  1994-02-04       Impact factor: 47.728

8.  Search for the molecular basis of morphological variation in Mycobacterium avium.

Authors:  S Prinzis; B Rivoire; P J Brennan
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

9.  Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages.

Authors:  C Perronne; A Gikas; C Truffot-Pernot; J Grosset; J L Vilde; J J Pocidalo
Journal:  Antimicrob Agents Chemother       Date:  1991-07       Impact factor: 5.191

10.  Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells.

Authors:  M B Carlier; A Zenebergh; P M Tulkens
Journal:  J Antimicrob Chemother       Date:  1987-11       Impact factor: 5.790

View more
  10 in total

1.  Observed differences in virulence-associated phenotypes between a human clinical isolate and a veterinary isolate of Mycobacterium avium.

Authors:  K A Birkness; W E Swords; P H Huang; E H White; C S Dezzutti; R B Lal; F D Quinn
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Resolution of Crohn's disease and complex regional pain syndrome following treatment of paratuberculosis.

Authors:  J Todd Kuenstner; William Chamberlin; Saleh A Naser; Michael T Collins; Coad Thomas Dow; John M Aitken; Stuart Weg; Grzegorz Telega; Kuruvilla John; David Haas; Torsten M Eckstein; Maher Kali; Christine Welch; Thomas Petrie
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

3.  Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection.

Authors:  Maurizio Renna; Catherine Schaffner; Karen Brown; Shaobin Shang; Marcela Henao Tamayo; Krisztina Hegyi; Neil J Grimsey; David Cusens; Sarah Coulter; Jason Cooper; Anne R Bowden; Sandra M Newton; Beate Kampmann; Jennifer Helm; Andrew Jones; Charles S Haworth; Randall J Basaraba; Mary Ann DeGroote; Diane J Ordway; David C Rubinsztein; R Andres Floto
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

4.  Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination.

Authors:  Irma A J M Bakker-Woudenberg; Wim van Vianen; Dick van Soolingen; Henri A Verbrugh; Michiel A van Agtmael
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

5.  Pathogenic mycobacteria disrupt the macrophage actin filament network.

Authors:  I Guérin; C de Chastellier
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

6.  Virulent Mycobacterium fortuitum restricts NO production by a gamma interferon-activated J774 cell line and phagosome-lysosome fusion.

Authors:  Tânia Regina Marques Da Silva; Juliana Ribeiro De Freitas; Queilan Chagas Silva; Cláudio Pereira Figueira; Eliana Roxo; Sylvia Cardoso Leão; Luiz Antônio Rodrigues De Freitas; Patrícia Sampaio Tavares Veras
Journal:  Infect Immun       Date:  2002-10       Impact factor: 3.441

7.  Differential antibiotic susceptibility of Mycobacterium abscessus variants in biofilms and macrophages compared to that of planktonic bacteria.

Authors:  Rebecca Greendyke; Thomas F Byrd
Journal:  Antimicrob Agents Chemother       Date:  2008-03-31       Impact factor: 5.191

8.  How type 1 fimbriae help Escherichia coli to evade extracellular antibiotics.

Authors:  Ima Avalos Vizcarra; Vahid Hosseini; Philip Kollmannsberger; Stefanie Meier; Stefan S Weber; Markus Arnoldini; Martin Ackermann; Viola Vogel
Journal:  Sci Rep       Date:  2016-01-05       Impact factor: 4.379

9.  BCG Vaccination Induces M. avium and M. abscessus Cross-Protective Immunity.

Authors:  Getahun Abate; Fahreta Hamzabegovic; Christopher S Eickhoff; Daniel F Hoft
Journal:  Front Immunol       Date:  2019-02-19       Impact factor: 7.561

10.  Foamy macrophages from tuberculous patients' granulomas constitute a nutrient-rich reservoir for M. tuberculosis persistence.

Authors:  Pascale Peyron; Julien Vaubourgeix; Yannick Poquet; Florence Levillain; Catherine Botanch; Fabienne Bardou; Mamadou Daffé; Jean-François Emile; Bruno Marchou; Pere-Joan Cardona; Chantal de Chastellier; Frédéric Altare
Journal:  PLoS Pathog       Date:  2008-11-11       Impact factor: 6.823

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.